Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03409614
Title	Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Regeneron Pharmaceuticals
Indications	lung non-squamous non-small cell carcinoma lung squamous cell carcinoma
Therapies	Cemiplimab + Ipilimumab Cemiplimab
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| FRA \| AUT